AU

BLUETTI Unlocks Special Mother's Day Offerings, Perfect Gift Ideas for Moms

Retrieved on: 
星期五, 五月 10, 2024
Mother, Jewellery, Camping, EB, UPS, Safety

From May 10-22, BLUETTI will be offering special discounts on its solar generators and power solutions, providing the perfect gift ideas for mothers and mother-like figures.

Key Points: 
  • From May 10-22, BLUETTI will be offering special discounts on its solar generators and power solutions, providing the perfect gift ideas for mothers and mother-like figures.
  • Additionally, these systems offer a personalized gift for moms, as their capacity is customizable from 3,072Wh to 18,432Wh with the B300S expansion battery.
  • To celebrate Mother's Day, BLUETTI is also adding exciting surprises, including a spin wheel for a chance to win fantastic gifts.
  • Everyone is invited to participate and seize these exclusive BLUETTI Mother's Day deals.

Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea

Retrieved on: 
星期三, 五月 8, 2024
FDA, Therapeutic Goods Administration, MFDS, EMA, Drug development, TGA, Pharmaceutical industry

Avance Clinical CEO, Yvonne Lungershausen said the decision to open clinical operations in Seoul followed increasing demand from later phase US biotechs, as well as CRO partners for access to the region's scientific excellence and patient populations.

Key Points: 
  • Avance Clinical CEO, Yvonne Lungershausen said the decision to open clinical operations in Seoul followed increasing demand from later phase US biotechs, as well as CRO partners for access to the region's scientific excellence and patient populations.
  • "The new South Korean operations also offer a strategic presence for Avance Clinical's CRO partners conducting multi-regional or global trials.
  • Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III.
  • Book a meeting with the team at the Australian Pavilion at BIO Korea to meet with our team of clinical trial experts.

BLUETTI Leads the Charge Towards Greener Living this Earth Day 2024

Retrieved on: 
星期一, 四月 15, 2024
Carbon, B300, Dust, Emergency, Camping, Earth Day, Longevity, Electronic waste, IP65, Renewable energy

SYDNEY, AU, Apr 15, 2024 - (ACN Newswire) - As Earth Day approaches, BLUETTI reaffirms its commitment to environmental stewardship with this year's theme -- "Embrace Our Earth, Energize Our Life".

Key Points: 
  • SYDNEY, AU, Apr 15, 2024 - (ACN Newswire) - As Earth Day approaches, BLUETTI reaffirms its commitment to environmental stewardship with this year's theme -- "Embrace Our Earth, Energize Our Life".
  • To minimize electronic waste, BLUETTI produces truly durable power products like the New AC240.
  • Living off the grid doesn't mean relying on traditional energy sources like firewood or fuel generators.
  • Join BLUETTI this Earth Day to embrace renewable energy and a brighter future.

BLUETTI AC240 Launches in Australia: The Ultimate All-Weather Power Solution

Retrieved on: 
星期二, 四月 2, 2024
Climate, Amazon, Emergency, LFP, UPS, Coffee, IP65

The AC240 promises to be the go-to power solution for outdoor enthusiasts with IP65 water resistance and dustproofing for reliable performance in any climate.

Key Points: 
  • The AC240 promises to be the go-to power solution for outdoor enthusiasts with IP65 water resistance and dustproofing for reliable performance in any climate.
  • Designed to withstand harsh conditions, the BLUETTI AC240 is dust-proof and resistant to low-pressure water jets.
  • With an impressive 2,400W output and 1,536Wh LFP battery, the AC240 offers versatile power solutions for a variety of outdoor adventures.
  • In the event of weather-related power outages in Australia, such as those caused by tropical storms, the AC240 serves as a reliable backup power source.

Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study

Retrieved on: 
星期四, 三月 28, 2024
FDA, Congress, Psoriasis, News, Food, Infection, GMO, Cell, Vaccine, Knowledge, OMICS Publishing Group, Hypertension, EMA, Drug development, Clinical trial, OGTR, COVID-19, TGA, RSV, Pharmaceutical industry

(Booth #267)

Key Points: 
  • (Booth #267)
    Avance Clinical CEO, Yvonne Lungershausen said the World Vaccine Congress was an important event for the company's US and Australian teams as they continue to excel in biotech vaccine CRO services.
  • Lungershausen said Avance Clinical is a mid-sized, agile, and responsive CRO with a proven track record of swiftly advancing high-quality clinical programs.
  • She said Avance Clinical is proud to be working with many innovative vaccine biotech companies including Uvax Bio who have just announced another milestone in their Phase I HIV study.
  • Lungershausen said Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III.

SafePest Control: Revolutionising Pest Management with the Launch of Smart Digital Rodent Bait Stations

Retrieved on: 
星期四, 五月 9, 2024
NSW, Environment, Heart, Risk, Trapping

SafePest Control, a leading provider of innovative pest management solutions, is proud to announce the launch of its latest breakthrough technology – Smart Digital Rodent Bait Stations.

Key Points: 
  • SafePest Control, a leading provider of innovative pest management solutions, is proud to announce the launch of its latest breakthrough technology – Smart Digital Rodent Bait Stations.
  • Safe pest control sydney recognises this need for efficient, humane, and intelligent solutions, leading to the development of its groundbreaking Smart Digital Rodent Bait Stations.
  • Unlike traditional pest control methods, these digital bait stations use cutting-edge technology to monitor rodent activity in real-time.
  • “With the launch of our Smart Digital Rodent Bait Stations, we are revolutionising the way pest control is approached,” said Milad Bahrami, CEO of SafePest Control.

Venom’s BlackBook Zero 14 honoured with HPL best business laptop award

Retrieved on: 
星期四, 五月 9, 2024
PC Gamer, HPL, Magnesium alloy, Glass, News, BlackBook, SMB, SOHO, Computer, TechRadar, WH, High, Intel Core, Facial recognition, APC, PC, DDR5, AC, SSD, Government, Windows 10, USB, PC World, Data-rate units, Video game

MELBOURNE, Australia, May 09, 2024 (GLOBE NEWSWIRE) -- Venom, manufacturer of performance orientated laptop computers has been recognised by HPL (High performance Laptops) for the Best Business laptop award.

Key Points: 
  • MELBOURNE, Australia, May 09, 2024 (GLOBE NEWSWIRE) -- Venom, manufacturer of performance orientated laptop computers has been recognised by HPL (High performance Laptops) for the Best Business laptop award.
  • The emphasis of the best business laptop award is on weight, battery life, screen quality and size, ports and connectivity, web conferencing, build quality, security and service level agreements.
  • Venom’s BlackBook Zero 14 Phantom G9 scored the highest in these categories overall thus winning the category award for best business laptop.
  • Factors contributing to the award are the BlackBook Zero 14 Phantom G9’s lightweight portable design and high-speed performance.

Skyborne Technologies Unveils the Cerberus Modular Integration

Retrieved on: 
星期四, 五月 9, 2024
Cerberus, AITR, System, IP, CBRNE, United States Army, CMI, MILSPEC, BDA, EW, UAS, Electronics, Robotics, Fort Moore, Rain, Artificial intelligence, CBO, Telescopic sight

BRISBANE, Australia, May 10, 2024 (GLOBE NEWSWIRE) -- Skyborne Technologies is proud to unveil Cerberus Modular Integration (MI), a multi-mission, man-packable, Group 2 sUAS equipped with modular kinetic and non-kinetic payloads.

Key Points: 
  • The old Cerberus GLH lacked the endurance, survivability and accuracy required for a real operation.
  • Adrian Dudok, CBO and co-founder, Skyborne Technologies, says, “Our customers asked for a multi-mission modular payload lethal small UAS capable of delivering organic low cost strike capability with the ability to perform non-kinetic sensors and effectors operations.
  • We’re proud to release the Cerberus MI to deliver a unique capability to our customers and the warfighter.
  • The new Cerberus MI will be landing in the hands of customers from Q4 this year.”
    Skyborne Technologies Pty Ltd, is an Australian defence technology company developing smart aerial robotics, with its flagship tri-tilt rotor lethal sUAS, Cerberus UAS.

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Retrieved on: 
星期三, 五月 8, 2024
Neurodegenerative disease, Neuroimaging, MSA, Safety, Pharmacokinetics, Food, ASX, Pathology, Disease, Data monitoring committee, Patient, DMC, Biomarker, Clinical trial, Therapy, ATH, Food and Drug Administration, SAN, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Key Points: 
  • The DMC conducted its prespecified review of unblinded clinical data from study participants.
  • The plan for the DMC to review clinical data from the trial has been cleared with the U.S. Food and Drug Administration.
  • “We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned,” said David Stamler, M.D., Chief Executive Officer of Alterity.
  • Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091 .

Amended & Restated Technical Report to Support Kharmagtai Preliminary Economic Assessment

Retrieved on: 
星期三, 五月 8, 2024
PFS, PEA, XAM, News, Technical report, Resource, Zijin Mining, TSX, ASX, SGC, Q3, Mineral Resources Limited, Disclosure, Ontario Securities Commission, National instrument, CIM, Cryptocurrency

TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) announces that the Company has filed an amended and restated independent National Instrument 43-101 technical report titled National Instrument 43-101 Amended and Restated Preliminary Economic Assessment Technical Report, Kharmagtai Copper-Gold Project, South Gobi, Mongolia (PEA), effective 4 April 2022.

Key Points: 
  • TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) announces that the Company has filed an amended and restated independent National Instrument 43-101 technical report titled National Instrument 43-101 Amended and Restated Preliminary Economic Assessment Technical Report, Kharmagtai Copper-Gold Project, South Gobi, Mongolia (PEA), effective 4 April 2022.
  • As a result of a review by staff of the Ontario Securities Commission, we are issuing the following news release regarding our disclosure of the Kharmagtai Project.
  • The PEA is amended and restated to include additional clarifications and confirmatory information related specifically to the following:
    Replacement of Andrew Stewart with Julien Lawrence as the independent qualified person for the amended and restated PEA.
  • The amended and restated PEA, dated 7 May 2024, may be found under the Company’s profile on SEDAR+ at https://www.sedarplus.ca and at www.xanadumines.com.